0.77, 95% CI 0.71-0.83),此優點與病人年齡、肺. 癌細胞型態無關. 3 。在第Ⅳ期NSCLC 患者中, ... cizumab to platinum-based chemotherapy as first-line treat-.
確定! 回上一頁